OncoViews

A virtual platform for healthcare professionals to share knowledge in oncology worldwide.
ACCREDITED & CME-CERTIFIED
Watch Our SessionsShare Your Patient Case

UPCOMING

Advanced Lung Cancers

Tuesday • 6 December 2022 • 5 PM (CET)

Edward B. Garon

Edward B. Garon

University of California, Los Angeles, USA

Solange Peters, MD-PhD

Solange Peters

Lausanne University Hospital, Switzerland

Enriqueta Felip

Enriqueta Felip

Vall d’Hebron University Hospital, Barcelona, Spain

AGENDA

Welcome & introduction by host
Solange Peters

Druggable since 2022: newly approved therapies in NSCLC
Solange Peters

Highlights of the year in targeted therapies

Enriqueta Felip

Highlights of the year in immunotherapies
Edward Garon

Oncology CME-certified Accreditation
Virtual Live Meeting:
2 CME Credits from Swiss Society of Medical Oncology

Share this on Social Media!

In this OncoViews, we will focus on the latest advances in metastatic lung cancer. Our host Solange Peters welcomes you for this recap of 2022 alongside a leading panel of experts in the field of targeted therapies and immuno-oncology, to discuss practice-changing studies and latest approvals.

Register Here

Do You Have An Account Already?
No need to sign up again: as a verified OncoViewer, you will have access to all our upcoming sessions. Simply login to participate in this session.


First Time On OncoViews?

Get Registered Now

Our Partners

This session is kindly supported by our partners with no influence on the content

EliLilly
Merck
Janssen
Amgen
MSD Logo

COMING SOON

Lung Cancer

hosted by Solange Peters
Lausanne University Hospital, Switzerland

Lung Cancer

Enriqueta Felip
Vall d’Hebron University Hospital, Barcelona, Spain

Lung Cancer

Edward B. Garon
David Geffen School of Medicine, UCLA, Los Angeles, USA
6 December 2022

Breast Cancer

hosted by Peter Dubsky
Breast Center St. Anna Hospital, Lucerne, Switzerland

Breast Cancer

Nadia Harbeck
Breast Center, University Hospital Munich, Germany

Breast Cancer

Khalil Zaman
Breast Center CHUV, Lausanne, Switzerland
13 December 2022

LATEST EVENTS

ROUNDTABLE
ROUNDTABLE
ASCO | WCGIC
ROUNDTABLE

Missed Any Session?

Watch Our Virtual Round-Tables Now On Demand!

We had great discussions on the latest in hematology and oncology, from WCLC, ASCO, ESMO & SABCS. All round-tables are recorded and available for you behind the login curtain. 

OUR FACULTY

Melanoma

Lung Cancer

GU Cancers

Women’s Cancers

GI Cancers

Hematology

FAQs

Will I be able to re-access the live discussions?

Yes, absolutely. All our live sessions are recorded and made available within 24 hours on our portal so that you can play it on demand as often as you like.

Does it cost me anything?

 Access to all our sessions are free of charge for healthcare professionals, students, scientists or other staff from universities, hospitals & research labs as well as policy & non-profit organisations and sponsoring partners. Only registrations by non-sponsoring industry representatives are subject to a fee.

Why do you need my details for registration?

In accordance with Swiss and European regulations, we require some information about you for verification purposes to ensure that the content of our initiatives is aimed at healthcare professionals and those involved in the science, management and treatment of cancer. We will not share your personal details with any sponsor or any third party - promised!

How can I get involved in the discussion?
Please feel submit your questions or patient cases before or during our live webinars! With that you will be able to interact and influence the discussion. Submit your question or a patient case here.

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

Countdown until our next OncoViews session

Watch Our Virtual Round-Tables on Latest in Oncology

The virtual round-table and online content is only accessible to students of medicine and life sciences, certified healthcare professionals, associated press, industry representatives and other stakeholders in the science, management and prevention of cancer.